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Diabetes, stress, pharmaceuticals, surgery, and phys-
ical trauma can lead to hyperglycemic conditions. A
consistent relationship has been found between
chronic inflammation and the cardiovascular compli-
cations of hyperglycemia. We hypothesized that car-
diomyopathy and vasculopathy resulting from acute
hyperglycemia are dependent on mannose-binding
lectin (MBL) and lectin complement pathway activa-
tion. Hyperglycemia was induced in wild-type (WT)
C57BL/6 and MBL-null mice after streptozotocin ad-
ministration. Echocardiographic data and tissue sam-
ples were collected after 4, 7, or 14 days of acute
hyperglycemia. Hyperglycemic WT mice demon-
strated dilated cardiomyopathy with significantly in-
creased short and long axis area measurements dur-
ing systole and diastole compared to hyperglycemic
MBL-null mice. The EC50 for acetylcholine-induced re-
laxation of mesenteric arterioles in WT mice after 4
days of hyperglycemia demonstrated a significant
loss of nitric oxide–mediated relaxation compared to
normoglycemic WT or hyperglycemic MBL-null mice.
Myocardial histochemistry and Western blot analysis
revealed a significant influx of macrophages, altered
morphology, and increased elastin and collagen de-
position in hyperglycemic WT hearts compared to
MBL-null hearts. Serum transforming growth fac-
tor-1 levels were significantly lower in hyperglyce-
mic MBL-null compared to WT mice, suggesting de-
creased profibrotic signaling. Together, these data
104suggest that MBL and the lectin complement pathway
play a significant role in vascular dysfunction and
cardiomyopathy after acute hyperglycemia. (Am J
Pathol 2012, 180:104–112; DOI: 10.1016/j.ajpath.2011.09.026)
Type 1 diabetes is an autoimmune disorder that results in
the destruction of the insulin-producing  cells in the
pancreas, reducing or eliminating the body’s ability to
produce insulin. More than 25.8 million people in the
United States (8.3% of the population) have been diag-
nosed with diabetes mellitus.1 Diabetic patients have in-
creased incidences of atherosclerosis, coronary artery
disease, and myocardial infarction.2,3 Diabetic patients
also have increased mortality, worse long-term prognosis
after myocardial infarction, and a higher risk of cardio-
myopathy compared to patients without diabetes.3–5
Similarly, acute hyperglycemia is reported in many crit-
ical care settings and is occasionally referred to as stress
diabetes or stress hyperglycemia.6,7 Acute hyperglyce-
mia was originally regarded as nonproblematic and po-
tentially beneficial during the fight-or-flight response in
critically ill adult patients, ensuring an adequate supply of
glucose to the brain and immune system. However, re-
cent data suggest an association between high glucose
levels at the time of admission and adverse outcomes.8
The question of whether acute hyperglycemia in critically
ill patients is simply related to disease severity or is an
independent risk factor for morbidity and mortality re-
mains to be fully elucidated.
Complement can be activated by three separate path-
ways: classical, alternative, and lectin (Figure 1). Com-
plement activation plays a role in diabetic cardiovascular
complications.9–11 Diabetic patients have a glycated
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inactive.12 CD59 glycation might lead to micro- and ma-
crovascular pathology, but the molecular mechanisms for
complement activation in hyperglycemic states are un-
known. Hansen and colleagues have identified higher
mannose-binding lectin (MBL) levels in patients with type
1 diabetes and its association with vascular complica-
tions.13–15 Interestingly, C1 inhibitor (which also inhibits
MBL-associated serine protease-2) reduces diabetic
macular edema.16
Our group recently demonstrated decreased dilated
cardiomyopathy, hypertrophic remodeling, and loss of
cardiac progenitor cells in MBL-null mice compared to
WT mice after 14 days of acute hyperglycemia.9 Further,
MBL binds to fructosamines, advanced glycation end
products.17 These findings suggest a role for lectin com-
plement pathway activation and/or the MBL complex in
diabetic cardiomyopathy. The purpose of the present
study was to further characterize the role of MBL and
complement activation in acute hyperglycemia-induced
cardio- and vasculopathy.
Materials and Methods
All procedures were reviewed and conducted according
to the institute’s Animal Care and Use Committee. All
experiments were performed under the standards and
principles set forth in the Guide for Care and Use of
Laboratory Animals, published by the NIH (publication
no. 85-23, revised 1996).
Animals
C57BL/6 (WT) mice (8 to 12 weeks old; Taconic Farms,
Hudson, NY) were used as background controls for ge-
netically modified animals with specific complement
component deletions [MBL-null and C2/factor (f) B–null
Figure 1. The lectin pathway is C1q, C1r, C1s, and antibody independent. P,
properdin.mice], as described previously.18,19 The following groupswere studied: i) WT; ii) MBL-null; iii) WT after 4, 7, or 14
days’ hyperglycemia; iv) MBL-null after 4, 7, or 14 days’
hyperglycemia; v) WT  anti-C5 monoclonal antibody
(BB5.1, 20 mg/kg20)  4 days’ hyperglycemia; vi) MBL
null recombinant human (rh) MBL (75 g i.p. daily19,21)
4 days’ hyperglycemia; and vii) C2/fB null  4 days’ hyper-
glycemia. Mice were housed four per cage and had unlim-
ited access to water and standard mouse chow.
Agents and Chemicals
Streptozotocin (STZ) and N-(methylnitrosocarbamoyl)--
D-glucosamine were purchased (Sigma-Aldrich, St.
Louis, MO). Citrated saline was purchased from Alexis
(Lausen, Switzerland). The rhMBL was a gift from Dr.
Kazue Takahashi.
Hyperglycemia Induction
Hyperglycemia was induced by a single injection of
freshly prepared STZ solution (200 mg/kg body weight,
i.p.) in citrated saline, pH 4.2. Urinary glucose was tested
on day 4 after injection and again before experimenta-
tion. Mice with urinary glucose levels greater than 500
mg/dL (measured with Glucostix; Diastix, Bayer, Elkhart,
IN) in both tests were considered hyperglycemic.
Glucose and Insulin Measurements
Serum samples were collected from nonfasted WT and
MBL-null mice at 4, 7, and 14 days after STZ injection and
from WT normoglycemic controls. Serum glucose was
measured with a Glucose Assay Kit (Cayman Chemical,
Ann Arbor, MI) per the manufacturer’s protocol. Serum
insulin levels were measured in the same groups using
an Ultra-Sensitive Mouse Insulin enzyme-linked immu-
nosorbent assay kit (Crystal Chem Inc., Downers Grove,
IL) as per the manufacturer’s protocol.
Endothelium-Dependent Relaxation
Anesthesia was induced and maintained with isoflurane.
After a midline laparotomy, the intestine was removed en
bloc with mesenteric vessels and placed in cold Krebs-
Henseleit buffer (Sigma-Aldrich). Mesenteric arterioles
with an internal diameter of 100 to 300 m were isolated,
attached to micropipettes, pressurized to 54 cm H2O,
and superfused with Krebs-Henseleit buffer (gassed with
95% O2 and 5% CO2 at 37°C) as previously de-
scribed.22–24 After equilibration for 45 minutes, vessels
were constricted to 50% to 70% of baseline with norepi-
nephrine (0.1 mol/L), and then endothelium-dependent
relaxation was induced by cumulative additions of ace-
tylcholine (ACh; 0.001 to 10 mol/L). Vessels that failed to
relax to baseline were subjected to sodium nitroprusside
(0.1 mol/L) to verify functional vascular smooth muscle.
All data were continuously recorded via VCR, and vessel
relaxation expressed as percentage relaxation from con-
stricted baseline as previously described.22
106 Pavlov et al
AJP January 2012, Vol. 180, No. 1Echocardiography
Transthoracic echocardiography was used to evaluate
cardiac functional parameters of the mice after 4 and
14 days of hyperglycemia. Echocardiography (Philips
Sonos 5500, Andover, MA; 7 to 15 MHz probe) was
performed as described measuring long and short axis
area during systole and diastole and used to calculate
ejection fraction (EF).9,19,25
Histology and Immunohistochemistry
Hearts were collected and fixed in 10% neutral buffered
formalin (Sigma-Aldrich, St. Louis, MO). Samples were
embedded in paraffin and sectioned (5 m) from apex to
midmyocardium for H&E and macrophage (Iba-1, Mac-2,
YM-1) and T-cell (CD3) evaluation. Slides were stained
for macrophages using a Trilogy (Cell Marque, Rocklin,
CA) steaming protocol. Briefly, slides were steamed in
two changes of Trilogy for a total of 1 hour. After steam-
ing, slides were cooled, rinsed with H2O, and incubated
in methanol/30% H2O2 for 20 minutes. Slides were rinsed
and blocked using Protein Block (Dako, Carpinteria, CA)
for 10 minutes. Sections were then incubated with Mac-2
(Cedarlane Laboratories, Burlington, NC), YM-1 (Stem-
cell Technologies, Vancouver, Canada), Iba-1 (Wako
Chemicals, Richmond, VA), or CD3 (Abcam, Cambridge,
MA) diluted with AB Diluent (Dako) for 1 to 2 hours at
room temperature. Mac-2 and YM-1 were visualized us-
ing the Vectastain Elite ABC kit (Vector, Burlingame, CA)
and Iba-1 or CD3 using the SuperPicture Kit (Invitrogen,
Carlsbad, CA). For collagen and elastin fibers identifica-
tion, hearts were collected in OCT (Sakura Finetek USA
Inc., Torrance, CA), frozen, and sectioned (5 m) from
apex to midmyocardium. Collagen staining was identified
by a Picrosirius Red Stain Kit (Polysciences Inc., War-
rington, PA) according to the manufacturer’s protocol.
Elastin fibers were identified with Verhoeff’s Elastin Stain
Kit (IMEB Inc., San Marcos, CA) according to the manu-
facturer’s protocol.
Heart Lysate and Western Blot Test
Additional cardiac tissue was collected, weighed, and
finely diced in radioimmunoprecipitation assay buffer
containing protease and phosphatase inhibitors, as per
the manufacturer’s recommendations (Santa Cruz, Santa
Cruz, CA). The tissue was homogenized using a Next-
Table 1. Serum Glucose and Insulin in WT and MBL Mice
Measurement
WT
Normoglycemic
MBL
Normoglycemic 4 days STZ
Glucose (mg/dL) 46.9  0.1 50.2  0.1 95.0  0.1*
Insulin (pg/mL) 250  31 259  69 ND
A significant increase and decrease in serum glucose and insulin lev
significant differences are observed between hyperglycemic WT and MB
data are mean  SEM of six animals per group.*P  0.01.
ND, results were below the detection limit of 100 pg/mL.Advance Bullet Blender and then centrifuged at 10,000
g for 10 minutes at 4°C. The resulting supernatant con-
tained the total cardiac cell lysate.
Protein concentrations were determined using a Bio-
Rad Protein Assay Kit (Bio-Rad, Hercules, CA). Western
blot testing was performed Bio-Rad 10% BioCast gels,
transferred onto nitrocellulose membranes, and blocked.
Membranes were incubated with a primary pAb against
collagen type IV (United States Biological, Swampscott,
MA), washed, incubated with a secondary goat anti-rab-
bit Ig near infrared fluorochrome (LI-COR IR700 nm; LI-
COR Biosciences, Lincoln, NE), and scanned using the
Odyssey system (LI-COR). Protein loading equivalence
was verified by probing for glyceraldehyde 3-phosphate
dehydrogenase.
TBARS
Overall oxidative stress was evaluated in the plasma of
WT and MBL-null mice and after 14 days of hyperglyce-
mia. Lipid peroxidation [malondialdehyde (MDA)-TBARS]
was measured in the plasma using the methods provided
by the manufacturer of OXItek (ZeptoMetrix, Buffalo, NY).
TGF-1 Enzyme-Linked Immunosorbent Assay
Transforming growth factor (TGF)-1 was determined
from mouse serum using the Quantikine Mouse TGF-1
Immunoassay Kit (R&D Systems, Minneapolis, MN).
Statistical Analysis
Data are presented as means  SEM. Comparisons be-
tween paired sets of data were made by Student’s t-test.
Analyses of variance were used for statistical compari-
sons of multiple groups followed by a Student-Newman-
Keuls test with P  0.05 being considered statistically
significant.
Results
STZ injection resulted in acute hyperglycemia and hypo-
insulinemia within 4 days after injection compared to nor-
moglycemic mice (Table 1). No significant differences in
serum glucose or insulin concentrations were observed
between WT and MBL-null mice at any time point after
STZ injection throughout the study (Table 1).
WT MBL null
ys STZ 14 days STZ 4 days STZ 7 days STZ 14 days STZ
 0.1* 113.1  0.2* 123.3  0.1* 109.2  0.1* 123.6  0.1*
D ND ND ND ND
e observed after administration of STZ in both groups, respectively. No
erum glucose or insulin levels at any of the experimental time points. All7 da
122.9
N
els wer
L-null s
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Hyperglycemia Is Significantly Decreased in
MBL-Deficient Mice
We previously observed echocardiographic evidence of
dilated cardiomyopathy after 14 days of hyperglycemia.9
In the present study, echocardiographic evidence of hy-
pertrophic myocardial remodeling appeared to be initi-
ated within 4 days of acute hyperglycemia (Figure 2).
Echocardiographic findings suggest that left ventricle
systolic function is impaired in hyperglycemic WT mice at
4 days with significantly increased short-axis area mea-
surements in systole compared to MBL-null mice. By day
14, we observed increased area measurements in the
short and long axis during systole in WT hearts compared
to MBL-null hearts. In diastole, on the other hand, we
observed decreased long-axis area measurements at 4
days of hyperglycemia, which we hypothesize is a result
of ventricular stiffening. In MBL-null mice, we observed a
significant decrease in short-axis area measurements in
diastole after 14 days of hyperglycemia.
Cardiac EF was significantly impaired in hyperglyce-
mic WT hearts as early as 4 days after hyperglycemia
induction (Figure 3). By day 14, we observed a further
and significant reduction in EF in hyperglycemic WT mice
compared to MBL-null mice, similar to what we observed
previously.9
MBL-Deficient Mice Are Protected from
Hyperglycemia-Induced Vasculopathy
Diabetes mellitus results in decreased nitric oxide (NO)-
mediated vascular relaxation,26 which has been ascribed
to increased oxidative stress in the diabetic state.27 We
investigated the oxidative state in our model by looking at
plasma MDA-TBARS levels after 14 days of hyperglyce-
mia. As shown in Figure 4A, we observed a significant
increase in plasma MDA after 14 days of hyperglycemia
in WT mice compared to normoglycemic WT mice. Fur-
Figure 2. Myocardial short (SA) and long (LA) axis area measurements.
Systolic and diastolic areas (cm2) were measured at 4 and 14 days of hyper-
glycemia. All data are mean  SEM of three animals per group.*P  0.05;
**P  0.02.thermore, MBL-null mice displayed the same magnitude
of oxidative stress as the WT mice after induction of
hyperglycemia. Thus, the oxidative stress level is not
significantly different in WT and MBL-null mice after STZ-
induced hyperglycemia.
After 4 days of hyperglycemia, WT mesenteric arteri-
oles had a significant loss of ACh-induced relaxation
compared to WT normoglycemic vessels (Figure 4B).
Further, ACh induced relaxation of arterioles from hyper-
glycemic MBL-null mice were not significantly different
from normoglycemic WT or MBL-null vessels. The EC50
for ACh-induced relaxation was increased (three orders
of magnitude) for hyperglycemic WT (5.0  2.9 mol/L)
compared to normoglycemic MBL-null (12  5 nmol/L),
normoglycemic WT (6  2 nmol/L), or MBL-null hypergly-
cemic (11  3 nmol/L) mice. Reconstitution of hypergly-
cemic MBL-null mice with rhMBL (75 g/mouse/day, i.p.)
restored hyperglycemia-induced vasculopathy (EC50 
2 1 mol/L) to WT hyperglycemic mice levels. These data
suggest that the loss of MBL alone is responsible for the
loss of NO-mediated relaxation after acute hyperglycemia.
Complement activation, particularly formation of
C5b-9, leads to loss of NO-mediated relaxation of arteries
and arterioles.22,28 To characterize the role of comple-
ment activation in the loss of NO-mediated relaxation
after acute hyperglycemia, we evaluated ACh-induced
relaxation of arterioles from hyperglycemic WT mice
treated with anti-C5 monoclonal antibody (BB5.1), as well
as from hyperglycemic C2/fB-deficient mice. As shown in
Figure 4C, genetic inhibition of complement activation
(eg, C2/fB-deficient mice) or immunotherapeutic inhibi-
tion of C5 cleavage (eg, BB5.1) attenuated the loss of
ACh-induced relaxation. The EC50 values for both of
these complement inhibited groups were located be-
tween that of hyperglycemic MBL-null and hyperglyce-
mic WT mice. Collectively, these data suggest that com-
plement activation contributes to the loss of NO-mediated
relaxation, which supports our previous findings.22,28
Figure 3. Myocardial EF measurements. EF was measured at 4 and 14 days of
hyperglycemia. All data are mean SEM of three animals per group. *P 0.05;
**P  0.02.However, the data also suggest the MBL complex con-
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after acute hyperglycemia because oxidative stress lev-
els between the two genotypes are not significantly dif-
ferent (Figure 4A).
Figure 4. A: Thiobarbituric acid reactive substances (MDA) in plasma after
14 days of hyperglycemia (STZ) versus normoglycemic (STZ) WT and
MBL-null mice; N  4 per group. *P  0.05 compared to respective nor-
moglycemic group. B: Microvascular endothelium-dependent relaxation of
mesenteric arterioles after 4 days of hyperglycemia. The EC50 for ACh-
induced relaxation of contracted arterioles; P  0.01. Hyperglycemic WT
arterioles have a significantly reduced capacity to relax to the endothelium
dependent reagent, ACh. C, control groups. Sodium nitroprusside relaxed all
vessels normally. N  6 per group.MBL Deficiency Results in Decreased Matrix
Deposition and Profibrotic Signaling
One of the hallmarks of hyperglycemia is vascular and
myocardial remodeling, where myocardial fibrosis is an
early manifestation.29 To examine whether MBL played a
role in myocardial remodeling, hyperglycemic hearts
were examined by Picrosirius red, Verhoeff’s elastin
staining and Western blot test to observe and quantify
extracellular matrix deposition. We found that cardiac
elastin and collagen deposition are increased in WT
hearts after 14 days of hyperglycemia compared to hy-
perglycemic MBL-null hearts (Figure 5). Western blot
analysis confirmed the histological observations and
demonstrated an increase in collagen type IV1 in hy-
perglycemic WT hearts compared to hyperglycemic
MBL-null hearts (Figure 6). Extracellular matrix deposition
is regulated through various signaling pathways, includ-
ing the profibrotic cytokine TGF-1.30 Serum TGF-1 lev-
els were significantly decreased in hyperglycemic MBL-
null mice compared to hyperglycemic WT mice (Figure
7). These data suggest that hyperglycemic MBL-deficient
mice are protected from myocardial remodeling, likely
involving TGF-1 signaling, at least in part.
Significant Myocardial Morphological Changes
in Hyperglycemic WT Mice
WT hearts demonstrated a moderate reduction in cardiac
muscle cross striations and increased hypereosinophilic
Figure 5. Cardiac elastin and collagen deposition are significantly increased
in hyperglycemic WT mice compared to normoglycemic WT or hyperglyce-
mic MBL-null mice. A: Representative photomicrographs of elastin-stained
(Verhoeff’s elastin stain) hearts obtained on day 14 of hyperglycemia com-
pared to normoglycemic WT mice. Significant elastin deposition was noted in
WT mice after 14 days of acute hyperglycemia (black, elastic fibers; red,
collagen; blue to black, nuclei). Original magnification, 40. B: Increased
extracellular matrix and collagen deposition (Picrosirius red stain) in WT
mice compared to MBL-null mice after 14 days of acute hyperglycemia (red,
collagen). Original magnification, 40.
Figure 6. Cardiac collagen deposition is significantly decreased in MBL-null
mice. Cardiac supernatants probed for collagen indicate a decrease in colla-
gen type IV in MBL-null hearts compared to WT hyperglycemic mice after 4
days of hyperglycemia.
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mice (Figure 8). Infiltration of myocardial inflammatory
cells in hyperglycemic WT hearts after 7 days of hyper-
glycemia were confirmed to be macrophages by staining
(Iba-1, Mac-2) (Figure 9). A significant decrease in Mac-2
staining was observed in hyperglycemic MBL-null com-
pared to WT mice at 7 and 14 days after induction of
hyperglycemia. Interestingly, few YM-1-positive cells
were observed in either group after 14 days of hypergly-
cemia (data not shown), suggesting that most of the
macrophages were Mac-2M1 cells.31 CD3 staining was
not different between the groups (data not shown). Thus,
MBL deficiency may lead to an anti-inflammatory state
within the myocardium during acute hyperglycemia.
Discussion
Whereas poor glycemic control has well-established ties
to microvascular and macrovascular disease, the link
with hard cardiovascular events is less clear. Recent
evidence suggests that hyperglycemic patients have the
same cardiovascular risk as patients who have had a
myocardial infarction.32 Further, acute hyperglycemic
disturbances are a potent predictor of mortality in pa-
tients without previously known diabetes mellitus.33
Complement is known to play a role in diabetes melli-
tus. Diabetic patients have a glycated form of CD59,
which renders this complement inhibitor inactive.12 CD59
Figure 7. Serum TGF-1 levels after 4 days of hyperglycemia in WT and
MBL-null mice. N  4 per group; *P  0.05.
Figure 8. Representative H&E-stained myocardial sections after 7 days of
hyperglycemia. Each panel represents one individual mouse heart. In WT
mice myocardium, cross striations are partially lost, together with hypereosi-
nophilic cytoplasm (circles). In MBL-null mice myocardium, clear cross
striations may be observed. Original magnification, 40.glycation is thought to lead to micro- and macrovascular
pathology in diabetic patients.34 Loss of CD59 function
may be important in protecting against loss of NO-in-
duced relaxation, as we previously demonstrated.28 Han-
sen and colleagues identified higher MBL levels in pa-
tients with type 1 diabetes and an association with
vascular complications.13–15 High serum MBL levels are
predictive for development of micro- or macroalbumin-
uria.35 Recently, MBL was demonstrated to bind to fruc-
tosamines, thereby establishing a potential ligand for
MBL binding and complement activation in acute hyper-
glycemia.17 Thus, MBL levels appear to be associated
with vascular complications in the diabetic patient.
In the present study, several important findings were
observed relating MBL deficiency and acute hyperglyce-
mia induced tissue injury, thus extending our previous
observations.9 First, hyperglycemic MBL-null mice had
significantly better cardiac ejection fractions compared
to hyperglycemic WT mice, especially after 14 days of
hyperglycemia. We previously demonstrated that MBL-
null mice were protected from myocardial injury after 2
weeks of uncontrolled hyperglycemia and were similar to
insulin-treated hyperglycemic mice.9 We extended those
previous findings by characterizing an earlier phase of
acute hyperglycemia. We observed significant left ven-
tricular systolic and diastolic dysfunction after only 4 days
of hyperglycemia in WT mice. These early differences
ultimately lead to a significant reduction in EF after 14
days of hyperglycemia in WT compared to the MBL-null
Figure 9. A: Representative immunohistochemistry of myocardial sections
after 7 days of hyperglycemia for macrophages (Mac-2). Original magnifica-
tion, 40 (right); 20 (left). B: Myocardial Mac-2-positive cells after 7 or 14
days of hyperglycemia in WT or MBL-null mice. *P  0.05 at 7 days, **P 
0.002 at 14 days of hyperglycemia compared to WT group.mice. These changes may be due, in part, to a loss of
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leading to impairments in myocyte regeneration.9,36,37
Second, WT arterioles had significantly decreased ability
to relax to the endothelium-dependent relaxing agent, ACh,
after only 4 days of hyperglycemia compared to arterioles
from hyperglycemic MBL-null mice. Both MBL-null and WT
mice displayed similar significant increases in plasma MDA
levels after 14 days of hyperglycemia, suggesting that the
amount of oxidative stress was similar and that the gener-
ation of reactive oxygen species alone cannot be respon-
sible for the difference in vascular reactivity observed in
this study. Previous studies have linked diabetes mellitus
to impaired NO signaling and enhanced oxidative stress,
resulting in endothelial dysfunction, inflammation, and
arterial remodeling.26,27 Our data suggest that either the
MBL complex or complement activation plays an impor-
tant role in the loss of vascular reactivity. We previously
demonstrated an important role of C5b-9 in mediating the
loss of NO-mediated relaxation in porcine and rat ves-
sels.22,28 Immunotherapeutic inhibition of murine C5 (eg,
monoclonal antibody BB5.1) or genetic depletion of C2
and fB (ie, inhibition of complement activation) demon-
strated an intermediate level of protection from hypergly-
cemia-induced loss of vascular reactivity compared to
MBL-null mice. Because MBL complexes are still present
and functional in anti-C5 monoclonal antibody treated WT
or C2/fB-null mice, these findings suggest complement
activation plays a partial role in disease progression.
Importantly, these data also indicate an essential role for
earlier complement components, including MBL and its
associated serine proteases, to establish the observed
vasculopathy. Furthermore, reconstitution of the lectin
pathway with rhMBL in MBL-null mice demonstrated that
NO-mediated relaxation is partially MBL complex depen-
dent. Reactive oxygen species are increased in acute
hyperglycemia.38,39 We previously demonstrated the im-
portant role of oxidative stress to up-regulate endothelial
cell MBL ligands, MBL complex activation, and ultimately
lectin complement pathway activation.40–42 Our present
findings support the hypothesis that oxidative stress
alone is not solely responsible for loss of NO-mediated
relaxation of arterioles and extends an important role for
MBL in cardiovascular complications and endothelial
dysfunction after acute hyperglycemia.
One of the consequences of endothelial cell dysfunc-
tion and NO loss is induction of an inflammatory state.
Type 1 diabetes is associated with a subclinical, chronic
inflammation, which is at least partly correlated to the
ensuing ischemia.43 Hyperglycemic MBL-null mice had
significantly less cardiac Mac-2 (M1) infiltration com-
pared to WT mice, whereas YM-1 cells (M2) were few in
number in both groups. It is still poorly understood
whether the presence of inflammation is the conse-
quence of or a marker for vascular damage. However,
studies suggest that a chronic inflammatory state likely
precedes and contributes to the pathogenesis and de-
velopment of micro- and macrovascular disorders in di-
abetes.43,44 Our data suggest that MBL complexes and
lectin pathway activation play a significant role in enhanc-
ing diabetes-induced inflammation, similar to that ob-
served after myocardial infarction.9,19Finally, profibrotic molecule production and extracel-
lular matrix deposition were significantly increased in hy-
perglycemic WT compared to MBL-null mice. Myocardial
fibrosis is an early manifestation of hypertrophic cardio-
myopathy.29 High glucose levels, leading to advanced
glycation end products formation, are associated with
TGF-1/Smad induction, collagen cross-linking, impaired
NO signaling, and enhanced oxidative stress.45,46
TGF-1 plays an important role in cardiac fibrogenesis,
endothelial-to-mesenchymal transition, and other ad-
vanced glycation end product–mediated diabetic com-
plications.47,48 TGF-1 increases connective tissue
growth factor expression, which induces monocyte/mac-
rophage migration, and cytokine and acute-phase pro-
tein production.49 TGF-1 expression and inflammatory
cell infiltrates were significantly decreased in hypergly-
cemic MBL-null mice compared to hyperglycemic WT
mice. Diabetic cardiomyopathy pathogenesis is likely
multifactorial, with excess extracellular matrix and inter-
stitial inflammation being hallmarks of the disease.50,51
Myocardial fibrosis and collagen deposition was ob-
served in hyperglycemic WT hearts as significant colla-
gen staining within myocardial and perivascular tissue.
Precisely how MBL deficiency is protective against struc-
tural remodeling in diabetes is unclear and will be inves-
tigated further by our laboratory in future studies. How-
ever, we hypothesize that reduced inflammation and
TGF-1 signaling likely play important roles.
In conclusion, a pathophysiological role for MBL in
hyperglycemia-induced cardiac fibrosis, systolic and di-
astolic dysfunction, and vascular reactivity was observed
in a model of acute hyperglycemia. Because 10% to 15%
of the population is functionally MBL deficient, it would be
of clinical interest to investigate whether functional MBL
serum levels correlate to cardiovascular complications
associated with hyperglycemia compared to patients un-
der adequate glycemic control. High-throughput screen-
ing for functional MBL levels is now possible, making this
relatively easy and testable hypothesis once an adequate
sample repository and database are available.52 A more
clinically relevant issue needs to be addressed in future
studies: does reduction of MBL levels improve outcomes
after establishment of the disease? This question can
only be addressed currently in humans until murine MBL
inhibitors are developed.41
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